Progress in biopharmaceutical development
Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believ...
Gespeichert in:
| Veröffentlicht in: | Biotechnology and applied biochemistry 2018-05, Vol.65 (3), p.306-322 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 322 |
|---|---|
| container_issue | 3 |
| container_start_page | 306 |
| container_title | Biotechnology and applied biochemistry |
| container_volume | 65 |
| creator | Kesik‐Brodacka, Malgorzata |
| description | Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believed to have great potential for further dynamic growth because of the tremendous demand for these drugs. Biobetters, which contain altered active pharmaceutical ingredients with enhanced efficacy, will play an important role in the development of biopharmaceuticals. Another significant group of biopharmaceuticals are biosimilars. Their introduction in the European Union and, recently, the Unites States markets will reduce the costs of biopharmaceutical treatment. This review highlights recent progress in the field of biopharmaceutical development and issues concerning the registration of innovative biopharmaceuticals and biosimilars. The leading class of biopharmaceuticals, the current biopharmaceuticals market, and forecasts are also discussed. |
| doi_str_mv | 10.1002/bab.1617 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6749944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2055178475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5047-e8059ca4e891e27c9e337a225488e536a54596cde5a6a225d1f70b376c67a0dc3</originalsourceid><addsrcrecordid>eNp1kEtLAzEQx4Motj7ATyAFL3rYmmTzvAi1-AJBD3oO2exUI7ubmnQrfnu3ttYHeBqY-fGbmT9CBwQPCcb0tLDFkAgiN1CfMIkzJRnbRH2sFM8YJ3kP7aT0gjFWUtFt1KNKS0q17KOT-xieIqQ08M2g8GH6bGNtHbQz72w1KGEOVZjW0Mz20NbEVgn2V3UXPV5ePIyvs9u7q5vx6DZzHDOZgcJcO8tAaQJUOg15Li2lnCkFPBeWM66FK4FbsWiXZCJxkUvhhLS4dPkuOlt6p21RQ-m61dFWZhp9beO7Cdab35PGP5unMDdCMq0Z6wTHK0EMry2kmal9clBVtoHQJkM0E4wqQWmHHv1BX0Ibm-49QzHnRCom-bfQxZBShMn6GILNIn_T5W8W-Xfo4c_j1-BX4B2QLYE3X8H7vyJzPjr_FH4AysuNjQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2055178475</pqid></control><display><type>article</type><title>Progress in biopharmaceutical development</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Kesik‐Brodacka, Malgorzata</creator><creatorcontrib>Kesik‐Brodacka, Malgorzata</creatorcontrib><description>Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believed to have great potential for further dynamic growth because of the tremendous demand for these drugs. Biobetters, which contain altered active pharmaceutical ingredients with enhanced efficacy, will play an important role in the development of biopharmaceuticals. Another significant group of biopharmaceuticals are biosimilars. Their introduction in the European Union and, recently, the Unites States markets will reduce the costs of biopharmaceutical treatment. This review highlights recent progress in the field of biopharmaceutical development and issues concerning the registration of innovative biopharmaceuticals and biosimilars. The leading class of biopharmaceuticals, the current biopharmaceuticals market, and forecasts are also discussed.</description><identifier>ISSN: 0885-4513</identifier><identifier>ISSN: 1470-8744</identifier><identifier>EISSN: 1470-8744</identifier><identifier>DOI: 10.1002/bab.1617</identifier><identifier>PMID: 28972297</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>biobetter ; biopharmaceutical ; Biopharmaceuticals ; Biopharmaceutics ; biosimilar ; Chemical industry ; Drug development ; drug market ; Drugs ; Humans ; Markets ; Medical treatment ; Monoclonal antibodies ; Pharmaceutical Preparations - chemical synthesis ; Pharmaceutical Preparations - chemistry ; Pharmaceuticals ; recombinant vaccines ; Review</subject><ispartof>Biotechnology and applied biochemistry, 2018-05, Vol.65 (3), p.306-322</ispartof><rights>2017 International Union of Biochemistry and Molecular Biology, Inc.</rights><rights>Copyright © 2018 International Union of Biochemistry and Molecular Biology, Inc.</rights><rights>2017 The Authors. published by Wiley Periodicals, Inc. on behalf of International Union of Biochemistry and Molecular Biology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5047-e8059ca4e891e27c9e337a225488e536a54596cde5a6a225d1f70b376c67a0dc3</citedby><cites>FETCH-LOGICAL-c5047-e8059ca4e891e27c9e337a225488e536a54596cde5a6a225d1f70b376c67a0dc3</cites><orcidid>0000-0003-1363-7986</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbab.1617$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbab.1617$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28972297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kesik‐Brodacka, Malgorzata</creatorcontrib><title>Progress in biopharmaceutical development</title><title>Biotechnology and applied biochemistry</title><addtitle>Biotechnol Appl Biochem</addtitle><description>Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believed to have great potential for further dynamic growth because of the tremendous demand for these drugs. Biobetters, which contain altered active pharmaceutical ingredients with enhanced efficacy, will play an important role in the development of biopharmaceuticals. Another significant group of biopharmaceuticals are biosimilars. Their introduction in the European Union and, recently, the Unites States markets will reduce the costs of biopharmaceutical treatment. This review highlights recent progress in the field of biopharmaceutical development and issues concerning the registration of innovative biopharmaceuticals and biosimilars. The leading class of biopharmaceuticals, the current biopharmaceuticals market, and forecasts are also discussed.</description><subject>biobetter</subject><subject>biopharmaceutical</subject><subject>Biopharmaceuticals</subject><subject>Biopharmaceutics</subject><subject>biosimilar</subject><subject>Chemical industry</subject><subject>Drug development</subject><subject>drug market</subject><subject>Drugs</subject><subject>Humans</subject><subject>Markets</subject><subject>Medical treatment</subject><subject>Monoclonal antibodies</subject><subject>Pharmaceutical Preparations - chemical synthesis</subject><subject>Pharmaceutical Preparations - chemistry</subject><subject>Pharmaceuticals</subject><subject>recombinant vaccines</subject><subject>Review</subject><issn>0885-4513</issn><issn>1470-8744</issn><issn>1470-8744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kEtLAzEQx4Motj7ATyAFL3rYmmTzvAi1-AJBD3oO2exUI7ubmnQrfnu3ttYHeBqY-fGbmT9CBwQPCcb0tLDFkAgiN1CfMIkzJRnbRH2sFM8YJ3kP7aT0gjFWUtFt1KNKS0q17KOT-xieIqQ08M2g8GH6bGNtHbQz72w1KGEOVZjW0Mz20NbEVgn2V3UXPV5ePIyvs9u7q5vx6DZzHDOZgcJcO8tAaQJUOg15Li2lnCkFPBeWM66FK4FbsWiXZCJxkUvhhLS4dPkuOlt6p21RQ-m61dFWZhp9beO7Cdab35PGP5unMDdCMq0Z6wTHK0EMry2kmal9clBVtoHQJkM0E4wqQWmHHv1BX0Ibm-49QzHnRCom-bfQxZBShMn6GILNIn_T5W8W-Xfo4c_j1-BX4B2QLYE3X8H7vyJzPjr_FH4AysuNjQ</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Kesik‐Brodacka, Malgorzata</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TB</scope><scope>7TK</scope><scope>7U5</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>L7M</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1363-7986</orcidid></search><sort><creationdate>201805</creationdate><title>Progress in biopharmaceutical development</title><author>Kesik‐Brodacka, Malgorzata</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5047-e8059ca4e891e27c9e337a225488e536a54596cde5a6a225d1f70b376c67a0dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>biobetter</topic><topic>biopharmaceutical</topic><topic>Biopharmaceuticals</topic><topic>Biopharmaceutics</topic><topic>biosimilar</topic><topic>Chemical industry</topic><topic>Drug development</topic><topic>drug market</topic><topic>Drugs</topic><topic>Humans</topic><topic>Markets</topic><topic>Medical treatment</topic><topic>Monoclonal antibodies</topic><topic>Pharmaceutical Preparations - chemical synthesis</topic><topic>Pharmaceutical Preparations - chemistry</topic><topic>Pharmaceuticals</topic><topic>recombinant vaccines</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kesik‐Brodacka, Malgorzata</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biotechnology and applied biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kesik‐Brodacka, Malgorzata</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progress in biopharmaceutical development</atitle><jtitle>Biotechnology and applied biochemistry</jtitle><addtitle>Biotechnol Appl Biochem</addtitle><date>2018-05</date><risdate>2018</risdate><volume>65</volume><issue>3</issue><spage>306</spage><epage>322</epage><pages>306-322</pages><issn>0885-4513</issn><issn>1470-8744</issn><eissn>1470-8744</eissn><abstract>Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believed to have great potential for further dynamic growth because of the tremendous demand for these drugs. Biobetters, which contain altered active pharmaceutical ingredients with enhanced efficacy, will play an important role in the development of biopharmaceuticals. Another significant group of biopharmaceuticals are biosimilars. Their introduction in the European Union and, recently, the Unites States markets will reduce the costs of biopharmaceutical treatment. This review highlights recent progress in the field of biopharmaceutical development and issues concerning the registration of innovative biopharmaceuticals and biosimilars. The leading class of biopharmaceuticals, the current biopharmaceuticals market, and forecasts are also discussed.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28972297</pmid><doi>10.1002/bab.1617</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-1363-7986</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-4513 |
| ispartof | Biotechnology and applied biochemistry, 2018-05, Vol.65 (3), p.306-322 |
| issn | 0885-4513 1470-8744 1470-8744 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6749944 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | biobetter biopharmaceutical Biopharmaceuticals Biopharmaceutics biosimilar Chemical industry Drug development drug market Drugs Humans Markets Medical treatment Monoclonal antibodies Pharmaceutical Preparations - chemical synthesis Pharmaceutical Preparations - chemistry Pharmaceuticals recombinant vaccines Review |
| title | Progress in biopharmaceutical development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T18%3A02%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progress%20in%20biopharmaceutical%20development&rft.jtitle=Biotechnology%20and%20applied%20biochemistry&rft.au=Kesik%E2%80%90Brodacka,%20Malgorzata&rft.date=2018-05&rft.volume=65&rft.issue=3&rft.spage=306&rft.epage=322&rft.pages=306-322&rft.issn=0885-4513&rft.eissn=1470-8744&rft_id=info:doi/10.1002/bab.1617&rft_dat=%3Cproquest_pubme%3E2055178475%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2055178475&rft_id=info:pmid/28972297&rfr_iscdi=true |